Key result
Long-term beta-blocker use falls below ~50% in post-MI patients due to physician concerns.
Why the study?
Should long-term beta-blockers be recommended for post-myocardial infarction patients?
Should long-term beta-blockers be recommended for post-myocardial infarction patients?
Despite strong guideline recommendations for long-term beta-blocker therapy post-MI, physician reluctance leads to significant underprescription in the chronic setting.
Answers are grounded in this paper and cite their sources.
Identifies a major gap in post-MI beta-blocker prescribing; leaves open whether indefinite guidelines require contemporary reevaluation.
ase 1: A 76-year-old man was diagnosed with an ST-segment elevation anterior wall myocardial infarction (MI) and underwent primary percutaneous coronary intervention with stent placement.After 3 days, the left ventricular ejection fraction was 35%.He was prescribed aspirin, clopidogrel, an angiotensin-converting enzyme (ACE) inhibitor, and a statin.Case 2: A 67-year-old woman with history of hypertension was diagnosed with a non-ST-elevation MI.The left ventricular ejection fraction was 50%.She initially was given an intravenous -blocker, nitrates, aspirin, an ACE inhibitor, and a statin.Should long-term -blockers be recommended for both of these patients?The 2001 American Heart Association and American College of Cardiology (AHA/ACC) guidelines for secondary prevention of MI and death recommend initiating -blockade in all post-MI patients and continuing therapy indefinitely.1 Despite strong evidence supporting the use of -blockers in the post-MI period, less than half of MI patients are prescribed -blockers in the chronic setting.2,3 Physician reluctance to use -blockers after acute MI may be related to: (1) a perceived decline of benefits due to the introduction of antiplatelet agents, ACE inhibitors, statins, and revascularization procedures; (2) concerns about safety in patients with heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus, and/or old age; (3) side effect profile; and (4) perceived lack of benefit in non-ST-elevation MI.
No takes yet. Share an insight, caveat, or question.
Gheorghiade et al. (2002) conducted a review in Myocardial Infarction. Beta-blockers was evaluated. Despite guideline recommendations for indefinite use, less than half of post-myocardial infarction patients are prescribed long-term beta-blockers due to physician concerns.
Synapse has enriched 10 related papers. Consider them for comparative context: